PACIFIC EDGE ORD FOR.EXEMPT NZX (PEB) Short Interest
PACIFIC EDGE ORD FOR.EXEMPT NZX (ASX:PEB) had 0.09% of shares reported as short positions as of 16 July 2026, representing 1,063,942 shares. PACIFIC EDGE ORD FOR.EXEMPT NZX operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Pacific Edge
Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PEB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Pacific Edge
Latest PEB news
All newsAbout
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PEB
Start a research thread or post the first pulse update